Published in Diabetes on August 01, 2004
Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest (2008) 5.27
Lipid-induced insulin resistance: unravelling the mechanism. Lancet (2010) 4.88
Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med (2012) 1.70
Functions of AMP-activated protein kinase in adipose tissue. J Physiol (2006) 1.70
Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance. Cell Metab (2012) 1.64
Non-invasive means of measuring hepatic fat content. World J Gastroenterol (2008) 1.60
The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment. J Lipid Res (2006) 1.50
Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids. Am J Physiol Endocrinol Metab (2008) 1.33
Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. World J Gastroenterol (2006) 1.21
Treatment of non-alcoholic fatty liver disease. Ther Clin Risk Manag (2007) 1.18
Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol (2013) 1.15
Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One (2012) 1.13
Peroxisome proliferator activated receptors and lipoprotein metabolism. PPAR Res (2008) 1.12
Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol (2008) 1.12
The role of metformin in the management of NAFLD. Exp Diabetes Res (2011) 1.09
Reduction of renal triglyceride accumulation: effects on proximal tubule Na+/H+ exchange and urinary acidification. Am J Physiol Renal Physiol (2009) 1.07
Betaine improved adipose tissue function in mice fed a high-fat diet: a mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol (2010) 1.03
Silymarin in non alcoholic fatty liver disease. World J Hepatol (2013) 1.03
The metabolic syndrome and nonalcoholic fatty liver disease in children. Curr Opin Pediatr (2009) 1.03
Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab (2010) 1.01
Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care (2013) 0.99
Insulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instability. Mediators Inflamm (2008) 0.99
Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. World J Gastroenterol (2006) 0.98
Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? World J Gastroenterol (2014) 0.93
Cardiometabolic aspects of polycystic ovarian syndrome. Vasc Health Risk Manag (2007) 0.93
Plasma Levels of Fatty Acid-Binding Protein 4, Retinol-Binding Protein 4, High-Molecular-Weight Adiponectin, and Cardiovascular Mortality Among Men With Type 2 Diabetes: A 22-Year Prospective Study. Arterioscler Thromb Vasc Biol (2016) 0.92
Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans. Am J Physiol Endocrinol Metab (2009) 0.90
Nocapyrones: α- and γ-pyrones from a marine-derived Nocardiopsis sp. Mar Drugs (2014) 0.90
The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial. Hepat Mon (2013) 0.90
Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion. J Diabetes Sci Technol (2009) 0.89
The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Therap Adv Gastroenterol (2011) 0.89
Optimizing combination treatment in the management of type 2 diabetes. Vasc Health Risk Manag (2007) 0.89
Intravenous fish oil lipid emulsion promotes a shift toward anti-inflammatory proresolving lipid mediators. Am J Physiol Gastrointest Liver Physiol (2013) 0.88
Prolonged treatment of genetically obese mice with conjugated linoleic acid improves glucose tolerance and lowers plasma insulin concentration: possible involvement of PPAR activation. Lipids Health Dis (2005) 0.87
Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease. J Diabetes Investig (2013) 0.87
Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. J Diabetes Complications (2007) 0.86
Effect of vildagliptin on hepatic steatosis. J Clin Endocrinol Metab (2015) 0.86
The role of clinical response to metformin in patients newly diagnosed with type 2 diabetes: a monotherapy study. Clin Exp Med (2014) 0.86
Advances in the treatment of nonalcoholic fatty liver disease. Ther Adv Endocrinol Metab (2010) 0.86
In vivo metabolic phenotyping of myocardial substrate metabolism in rodents: differential efficacy of metformin and rosiglitazone monotherapy. Circ Cardiovasc Imaging (2009) 0.86
Up- and down-regulation of adiponectin expression and multimerization: mechanisms and therapeutic implication. Biochimie (2012) 0.84
Steatosis and steatohepatitis: complex disorders. Int J Mol Sci (2014) 0.83
Components of metabolic syndrome and 5-year change in insulin clearance - the Insulin Resistance Atherosclerosis Study. Diabetes Obes Metab (2013) 0.83
Distinct metabolic effects following short-term exposure of different high-fat diets in male and female mice. Endocr J (2014) 0.83
The effects of macronutrient intake on total and high-molecular weight adiponectin: results from the OMNI-Heart trial. Obesity (Silver Spring) (2009) 0.83
Hepatic function and the cardiometabolic syndrome. Diabetes Metab Syndr Obes (2013) 0.83
Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes. Diabetes Obes Metab (2011) 0.83
Insulin Production and Resistance in Different Models of Diet-Induced Obesity and Metabolic Syndrome. Int J Mol Sci (2017) 0.83
Non-alcoholic fatty liver disease and diabetes. Metabolism (2016) 0.82
Pioglitazone increases whole body insulin sensitivity in obese, insulin-resistant rhesus monkeys. PLoS One (2015) 0.81
Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes. J Investig Med (2012) 0.81
Pharmacology of stone disease. Adv Chronic Kidney Dis (2009) 0.81
Pharmacotherapy for Nonalcoholic Fatty Liver Disease. Semin Liver Dis (2015) 0.81
Metformin increases plasma ghrelin in Type 2 diabetes. Br J Clin Pharmacol (2009) 0.80
Insulin resistance, hepatic lipid and adipose tissue distribution in HIV-infected men. Antivir Ther (2008) 0.80
The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patients. PPAR Res (2008) 0.80
AMPK Activation by Metformin Suppresses Abnormal Extracellular Matrix Remodeling in Adipose Tissue and Ameliorates Insulin Resistance in Obesity. Diabetes (2016) 0.80
Activation of the GP130-STAT3 axis and its potential implications in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol (2015) 0.79
Transcriptomic analysis of insulin-sensitive tissues from anti-diabetic drug treated ZDF rats, a T2DM animal model. PLoS One (2013) 0.79
Downregulation of ADIPOQ and PPARγ2 gene expression in subcutaneous adipose tissue of obese adolescents with hepatic steatosis. Obesity (Silver Spring) (2010) 0.79
Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study. J Diabetes Sci Technol (2009) 0.78
Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Technol Ther (2013) 0.78
Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes. Diabetologia (2008) 0.78
Treatment options for nonalcoholic Fatty liver disease. Therap Adv Gastroenterol (2008) 0.77
Pathogenesis and Prevention of Hepatic Steatosis. Gastroenterol Hepatol (N Y) (2015) 0.76
Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD). Am J Transl Res (2016) 0.76
A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes. Vasc Health Risk Manag (2007) 0.76
The double trouble of metabolic diseases: the diabetes-cancer link. Mol Biol Cell (2015) 0.76
Glucose supply and insulin demand dynamics of antidiabetic agents. J Diabetes Sci Technol (2010) 0.76
Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Gastroenterol Res Pract (2016) 0.76
Impact of pioglitazone on bone mineral density and bone marrow fat content. Osteoporos Int (2017) 0.75
A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy. Can J Kidney Health Dis (2016) 0.75
Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination. Vasc Health Risk Manag (2007) 0.75
Cardioprotective mechanisms of lifestyle modifications and pharmacotherapies on cardiac remodeling and dysfunction in hypertensive heart disease: an overview. Nagoya J Med Sci (2011) 0.75
All-trans retinoic acid shifts rosiglitazone-induced adipogenic differentiation to osteogenic differentiation in mouse embryonic fibroblasts. Int J Mol Med (2016) 0.75
PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis. Front Endocrinol (Lausanne) (2017) 0.75
Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab (2002) 6.79
Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol (2007) 3.83
Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology (2009) 3.67
Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care (2005) 3.60
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care (2009) 2.75
Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects--a monozygotic twin study. PLoS One (2007) 2.38
FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol (2011) 2.36
Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol (2008) 2.33
From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis (2010) 2.24
Liver fat in the metabolic syndrome. J Clin Endocrinol Metab (2007) 2.17
Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes (2007) 2.08
Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes (2007) 2.06
Global transcript profiles of fat in monozygotic twins discordant for BMI: pathways behind acquired obesity. PLoS Med (2008) 1.94
Association of lipidome remodeling in the adipocyte membrane with acquired obesity in humans. PLoS Biol (2011) 1.89
Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans. Am J Clin Nutr (2012) 1.80
Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology (2008) 1.78
Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes (2003) 1.71
Genetic variation in PNPLA3 but not APOC3 influences liver fat in non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2012) 1.67
Physical inactivity and obesity: a vicious circle. Obesity (Silver Spring) (2008) 1.65
Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab (2007) 1.64
Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab (2005) 1.62
Lowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilatation in obese women with previous gestational diabetes. Diabetes Care (2003) 1.56
Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care (2011) 1.53
Endogenous interleukin-10 protects against hepatic steatosis but does not improve insulin sensitivity during high-fat feeding in mice. Endocrinology (2006) 1.51
Comparison of lipid and fatty acid composition of the liver, subcutaneous and intra-abdominal adipose tissue, and serum. Obesity (Silver Spring) (2009) 1.39
Many patients with Type 1 diabetes estimate their prandial insulin need inappropriately. J Diabetes (2010) 1.39
Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS (2002) 1.34
Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol (2002) 1.33
The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans. Diabetes (2005) 1.32
Liver-fat accumulation and insulin resistance in obese women with previous gestational diabetes. Obes Res (2002) 1.31
Fatty acid metabolism in adipose tissue, muscle and liver in health and disease. Essays Biochem (2006) 1.27
Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. J Am Coll Cardiol (2008) 1.26
Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes (2008) 1.24
Use of genome-wide expression data to mine the "Gray Zone" of GWA studies leads to novel candidate obesity genes. PLoS Genet (2010) 1.24
Brain metabolic alterations in patients with type 1 diabetes-hyperglycemia-induced injury. J Cereb Blood Flow Metab (2004) 1.23
Congruence between NOTCH3 mutations and GOM in 131 CADASIL patients. Brain (2009) 1.23
Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care (2010) 1.21
Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J Clin Endocrinol Metab (2004) 1.21
High calcium diet down-regulates kidney angiotensin-converting enzyme in experimental renal failure. Kidney Int (2004) 1.20
Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care (2007) 1.16
Growth patterns in young adult monozygotic twin pairs discordant and concordant for obesity. Twin Res (2004) 1.15
Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. J Clin Endocrinol Metab (2003) 1.13
Altered miRNA processing disrupts brown/white adipocyte determination and associates with lipodystrophy. J Clin Invest (2014) 1.12
Low-grade gliomas and focal cortical developmental malformations: differentiation with proton MR spectroscopy. Radiology (2004) 1.11
Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J Clin Endocrinol Metab (2006) 1.11
Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab (2006) 1.10
Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial. Antivir Ther (2007) 1.09
Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study. Antivir Ther (2003) 1.09
Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol (2010) 1.08
One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis (2010) 1.07
Acquired obesity is associated with increased liver fat, intra-abdominal fat, and insulin resistance in young adult monozygotic twins. Am J Physiol Endocrinol Metab (2004) 1.06
Genetic variation in the ADIPOR2 gene is associated with liver fat content and its surrogate markers in three independent cohorts. Eur J Endocrinol (2009) 1.06
Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy. Am J Physiol Endocrinol Metab (2008) 1.06
Non-alcoholic and alcoholic fatty liver disease - two diseases of affluence associated with the metabolic syndrome and type 2 diabetes: the FIN-D2D survey. BMC Public Health (2010) 1.05
PNPLA3 mediates hepatocyte triacylglycerol remodeling. J Lipid Res (2014) 1.05
Acquired obesity and poor physical fitness impair expression of genes of mitochondrial oxidative phosphorylation in monozygotic twins discordant for obesity. Am J Physiol Endocrinol Metab (2008) 1.04
Acquired obesity increases CD68 and tumor necrosis factor-alpha and decreases adiponectin gene expression in adipose tissue: a study in monozygotic twins. J Clin Endocrinol Metab (2006) 1.04
Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. Am J Clin Nutr (2004) 1.03
PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis. Am J Physiol Endocrinol Metab (2012) 1.03
Postprandial lipemia associates with liver fat content. J Clin Endocrinol Metab (2007) 1.02
Liver fat and lipid oxidation in humans. Liver Int (2009) 1.01
Insulin-like growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity. J Clin Endocrinol Metab (2008) 1.01
Comparison of the relative contributions of intra-abdominal and liver fat to components of the metabolic syndrome. Obesity (Silver Spring) (2010) 0.99
Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity. Arterioscler Thromb Vasc Biol (2002) 0.99
Arterial stiffness in HIV-infected patients receiving highly active antiretroviral therapy. Antivir Ther (2005) 0.99
Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. J Clin Endocrinol Metab (2003) 0.98
Insulin- and exercise-stimulated skeletal muscle blood flow and glucose uptake in obese men. Obes Res (2003) 0.97
Adipose tissue gene expression analysis reveals changes in inflammatory, mitochondrial respiratory and lipid metabolic pathways in obese insulin-resistant subjects. BMC Med Genomics (2012) 0.96
Insulin regulation of MCP-1 in human adipose tissue of obese and lean women. Am J Physiol Endocrinol Metab (2008) 0.95
Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids. Diabetologia (2013) 0.95
Comparison of dorsocervical with abdominal subcutaneous adipose tissue in patients with and without antiretroviral therapy-associated lipodystrophy. Diabetes (2011) 0.94
Stimulus-induced brain lactate: effects of aging and prolonged wakefulness. J Sleep Res (2004) 0.94
Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses. J Clin Endocrinol Metab (2007) 0.94
Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. Am J Clin Nutr (2011) 0.93
3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol (2003) 0.93
Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease. Gastroenterology (2010) 0.93
Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity. Diabetes (2013) 0.92
Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins. J Hepatol (2009) 0.92
Increased resting energy expenditure, fat oxidation, and food intake in patients with highly active antiretroviral therapy-associated lipodystrophy. Am J Physiol Endocrinol Metab (2006) 0.91
Endothelial dysfunction in human diabetes. Curr Diab Rep (2002) 0.91
Open four-compartment model in the measurement of liver perfusion. Acad Radiol (2005) 0.89
Energy and nutrient intakes and adherence to dietary guidelines among Finnish adults with type 1 diabetes. Ann Med (2010) 0.89